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Abstract
CD20 negative B cell non-Hodgkin lymphoma (NHL) is rare and accounts for approximately 1-2% of B cell
lymphomas. CD20- negative NHL is frequently associated with extranodal involvement, atypical morphology,
aggressive clinical behaviour, resistance to standard chemotherapy and poor prognosis. The most common
types of these include plasmablastic lymphoma, primary effusion lymphoma, large B-cell lymphoma arising
from HHV8-associated multicentric Castleman’s disease, and ALK+ large B cell lymphoma. This review provides
an overview of the diagnostic and treatment modalities for CD20 negative B cell NHL.
Background
CD20 is a glycosylated phosphoprotein expressed on
the surface of all B cells (except early pro-B cells and
plasma cells). Human CD20 molecule is encoded by the
MS4A1 gene located on chromosome 11q12.2 [1, 2].
CD20 molecule is a tetra-transmembrane polypeptide
with 297 amino acid residues. It plays a role in the dif-
ferentiation, maturation and activation of B cells. CD20
is involved in the phosphorylation cascade of intracellu-
lar proteins by binding to Src family tyrosine kinases,
such as Lyn, Fyn, and Lck. The CD20 molecule remains
on the membrane of B cells without dissociation or
internalization upon binding of CD20 antibody. CD20
expression varies in different lymphoma subtypes [3–5].
It is present from late pro-B cells through memory B
cells, but not on early pro-B cells, plasmablasts and
plasma cells. Plasma cell differentiation of B cells re-
sults in acquisition of plasma cell markers and loss of B
cell antigens including the expression of CD20. CD20
was first defined by the murine monoclonal antibody
(MoAb) tositumomab [6, 7]. Rituximab, a chimeric
CD20 MoAb, was later developed and approved for
treatment of human B cell malignancies. Rituximab de-
stroys B lymphoid malignancies through complement-
dependent cytotoxicity (CDC) and antibody-dependent
cellular cytotoxicity (ADCC). The addition of rituxi-
mab, to cyclophosphamide, doxorubicin, vincristine,
and prednisone (CHOP) has dramatically improved the
survival of patients with diffuse large B cell lymphoma
(DLBCL) [8, 9]. R-CHOP has since become the gold
standard for the treatment of newly diagnosed DLBCL. In
addition, rituximab has been found highly effective in a
variety of B cell malignancies as well as relapsed and re-
fractory lymphomas. Through recombinant DNA technol-
ogy, second- and third- generation CD20 MoAbs were
developed [2]. Among these, ofatumumab and obinutuzu-
mab have been approved for clinical treatment of B cell
malignancies, such as chronic lymphoid leukemia, and
follicular lymphoma [10–15].
Genetic mutations of MS4A1 leading to conform-
ational changes in the protein have been speculated to
be a molecular mechanism of the CD20 negative pheno-
type [16]. The loss of CD20 expression is associated with
extranodal involvement, a more aggressive clinical course,
loss of responsiveness to rituximab and conventional
chemotherapy, leading to poor prognosis. It poses a diag-
nostic and therapeutic dilemma and further studies need
to be undertaken to establish the standard of care in this
group of patients.
CD20 negative non-Hodgkin lymphomas
The pan-B lymphocyte markers include CD19, CD20,
CD79a, and PAX-5 [2, 17–19]. Almost all B cell NHLs are
positive for CD20. CD20- negative NHLs are rare with a
rate of 1–2% of all B cell NHLs [20]. The most common
types of these include plasmablastic lymphoma, primary
effusion lymphoma, large B-cell lymphoma arising from
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HHV8-associated multicentric Castleman’s disease, and
ALK+ large B cell lymphoma [20, 21].
Plasmablastic lymphoma (PBL) is the most common
subtype of CD20 negative DLBCL, accounting for 75% of
the cases with a median survival of 12 months [22, 23].
PBL is frequently associated with HIV and/or Epstein-
Barr virus (EBV) co-infection. Immunoblastic lymphoma
is frequently related and can be difficult to differentiate
from PBL.
Primary effusion lymphoma (PEL), as the name sug-
gests, presents as pleural, peritoneal and/or pericardial
effusion. It is associated with HIV, EBV, and human
herpesvirus 8 (HHV8) co-infection and has a median
survival of 9 months [24].
Large B-cell lymphoma arising from HHV8-associated
multicentric Castleman disease (MCD) usually presents in
the setting of HIV infection. Unlike HHV-8 associated
PEL, large B-cell lymphomas arising from MCD frequently
has unmutated immunoglobulin IgM and lambda-chain
restriction, suggesting an origin from HHV-8- positive
plasmablasts [25].
Anaplastic lymphoma kinase (ALK) -positive DLBCL is
a very rare type of DLBCL [26]. Unlike ALK+ anaplastic
large cell lymphoma which harbors the ALK-NPM fusion
gene from t(2;5) translocation with favorable prognosis,
ALK+ DLBCL usually has t(2;17) (p23; q23) translocation
which leads to a fusion gene of ALK-CLTC [27, 28].
Unlike the common DLBCL, ALK+ DLBCL is usually
positive for CD38, CD138, and negative for CD20, CD30,
and CD79a [28]. This type of lymphoma has a median sur-
vival of 20 months.
In addition to the above rare CD20 negative lymph-
omas, CD20 positive lymphoma can relapse as CD20
negative lymphoma after CD20 antibody therapy [29].
Diagnosis of CD20 negative NHL
DLBCL is identified by morphology and B cell bio-
marker analysis by immunohistochemistry and flow
cytometry studies. However, CD20 negative DLBCL can
pose a diagnostic dilemma. Immunohistochemical de-
tection of CD19, CD79a and PAX-5 are the major bio-
markers in establishing the diagnosis of CD20 negative
B cell lymphoma. CD5 expression in DLBCL is mostly
associated with Richter’s transformation from a low-
grade B-cell lymphoma, but has been seen in 5% of de
novo DLBCL [30]. Similarly, CD10 expression is seen
in both de novo DLBCL as well as in transformed fol-
licular lymphomas [31]. Oct-2, Bob-1, and SOX11 are
frequently examined and useful for differential diagno-
sis and accurate classification of lymphoma diagnosis
[32, 33]. Flow cytometric analysis can reveal positivity
for CD19, CD79a, CD5 and CD10 in cases of CD20
negative lymphoma.
Molecular analysis using cytogenetics or FISH (fluor-
escent in-situ hybridization) to detect rearrangements or
translocations of Bcl-2, Bcl-6 and MYC is an important
part of diagnosis. BCL-2 mutation was found frequently
in human B cell lymphomas [34, 35]. Rearrangements or
translocations of both BCL-2 and MYC are hallmarks of
“double-hit” lymphomas which are typically more resist-
ant to R-CHOP and portent poor prognosis. More inten-
sive chemotherapy regimens and new agents like
ibrutinib and lenalidomide appear to improve responses
in these double-hit lymphomas [36].
Treatment strategies
There is still no standard of care for CD20 negative B
cell lymphomas. Response to standard CHOP chemo-
therapy is inadequate. CODOX-M/IVAC (cyclophospha-
mide, vincristine, doxorubicin, methotrexate alternating
with ifosfamide, etoposide, cytarabine) [37–44], dose-
adjusted EPOCH (infusional etoposide, vincristine and
doxorubicin along with bolus cyclophosphamide and
prednisone) [45–47], and HyperCVAD (cyclophospha-
mide, vincristine, doxorubicin and dexamethasone alter-
nating with high-dose methotrexate and cytarabine)
[48–52], are the suggested therapies. Upregulation of the
expression of CD20 in CD20-negative B cell acute
lymphoblastic leukemia following treatment with 5-
azacytidine has been reported [53]. In addition, good re-
sponse to bortezomib in combination with infusional
dose-adjusted EPOCH for the treatment of plasmablastic
lymphoma has also been reported [54]. Upregulation of
CD20 expression by epigenetic agents may be another
option to re-sensitize B lymphoma to CD20 antibodies
[55]. Plerixafor, a CXCR4 antagonist, has been shown to
enhance rituximab-induced killing of lymphoma cells
[56]. It would be interesting to examine whether plerixa-
for can have similar effect in CD20 negative lymphomas.
Conclusion
CD20 negative lymphoma is uncommon and has poor
prognosis. It poses a diagnostic and therapeutic dilemma.
Further studies need to be undertaken to establish the
standard of care for this group of patients. Novel agents
targeting B cell signalling pathways, such as, inhibitors of
Bruton tyrosine kinase and phosphoinositol-3 kinase, may
play important role in the therapy of this rare entity of B
cell lymphomas [57–62]. PD-1 antibodies are active in
lymphomas [63–65], it remains important to evaluate
whether immune check point inhibitors have activity in
CD20 negative lymphomas. Bcl-2 inhibitors may be an-
other option for CD20 negative lymphomas and warrant
further investigations [34, 66, 67].
Abbreviations
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